The study further demonstrated the utilization of combined inhibition of mTORC1/2 and PI3K as a potential therapeutic strategy to inhibit the progression of pancreatic cancer (Driscoll et al., 2016). Here, PIK3CA is linked to familial pancreatic carcinoma.